Clinical Trials
2
Active:0
Completed:0
Trial Phases
1 Phases
Phase 1:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
2 (100.0%)Lamivudine for Solid Tumors
Phase 1
Recruiting
- Conditions
- Relapsed/Refractory Solid Tumors
- Interventions
- Drug: PD-L1 Blocker
- First Posted Date
- 2024-07-10
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- Thomas Marron
- Target Recruit Count
- 24
- Registration Number
- NCT06494579
- Locations
- 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
Dupilumab_Metastatic NSCLC
Phase 1
Recruiting
- Conditions
- Metastatic Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2021-08-19
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- Thomas Marron
- Target Recruit Count
- 21
- Registration Number
- NCT05013450
- Locations
- 🇺🇸
Tisch Cancer Institute, Mount Sinai Hospital, New York, New York, United States
🇺🇸The Blavatnik Family-Chelsea Medical Center at Mount Sinai, New York, New York, United States
News
No news found